Attached files
Exhibit 10.62
AMENDED FINDER'S FEE AGREEMENT
THIS
AMENDMENT TO THE AMENDED FINDER'S FEE AGREEMENT IS DATED JUNE 11,
2020 (the Effective Date")
BETWEEN:
Guided
Therapeutics Inc., a US registered public company incorporated in
the State of Delaware with a registered and records office at 5835
Peachtree Corners East, Suite B Norcross GA 30092.
("the
Company")
AND
Fieldhouse
Capital Management Inc., a British Columbia, Alberta, Saskatchewan,
Manitoba, and Ontario Registered Exempt Market dealer with a
registered and records office at 230 -11 Mainland St., Vancouver,
BC V6B 5L1..
("the
Finder")
The
Company and the Finder hereby amend the Finder's Agreement
previously entered into by the parties
on or about April 10, 2019 in the following regards:
WHEREAS:
A.
The parties entered into an Amended Finder's Fee Agreement dated on
or about May 22, 2020 in regards to a completed Series D Financing
in December 2019 and the Company is in the process of closing a
2020 Series E Preferred Share Financing. which the parties agree is
to be further amended.
B.
Unchanged.
C.
Unchanged.
1.
FINDER SERVICES AND FEES 1.1-1.3 Unchanged
1.4
Finder's Fees. The Company agrees to provide the following
consideration to the Finder:
(a)
As an approved Finder, payment in cash consisting of:
i)
Five Percent (5%) of the gross proceeds raised ("GPR") from all
accepted subscription agreements for the 2020 Series E Preferred
Share financing ("2020 Financing") from investors introduced to the
Company by the Finder (the "Fee").
ii)
Two percent (2%) from the 2019 Series D financing only (which
amounts to $15,260 based on gross proceeds of
$763,000).
iii)
Based on the GPR by Finder, there shall be a payment to Finder
based on the percentages and caps shown in the table below from the
exercise of any warrants for the period of 3 years after the 2020
Financing that have been or will be issued in connection with this
and prior financings and debt settlements ("warrant exercise
commissions"); provided however that warrant exercise commissions
shall expire three (3) years from the close of the 2020
Financing.
b)
Deleted
1.5.
Fee Payment Terms: The Fee shall be paid within 5 business days
after all funds have been received by the Company in the 2020
Financing.
1.6-1.7:
Unchanged.
2.
TERM OF AGREEMENT
2.1.
The term of this agreement shall be three (3) years from the close
of the 2020 Series E Financing.
3-9.
Unchanged. IN WITNESS WHEREOF this Amendment has been executed by
the parties hereto on the Effective Date.
Guided
Therapeutics, Inc.
By:
/Gene Cartwright/
Title:
CEO & President
Fieldhouse
Capital Management, Inc
By:
/Douglas Sereda/
Title:
Chief Executive Officer (CEO) Director